| DEMLOVÁ, Regina, Dalibor VALÍK, Radka OBERMANNOVÁ a Lenka ZDRAŽILOVÁ DUBSKÁ. The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors. Physiological Research. Praha: Fyziologický ústav AV ČR, 2016, roč. 65, Suppl. 4, s. "S455"-"S462", 8 s. ISSN 0862-8408. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1369176,
author = {Demlová, Regina and Valík, Dalibor and Obermannová, Radka and Zdražilová Dubská, Lenka},
article_location = {Praha},
article_number = {Suppl. 4},
keywords = {Cancer treatment; Monoclonal antibodies; Immune checkpoint inhibitors; Immune related adverse events},
language = {eng},
issn = {0862-8408},
journal = {Physiological Research},
title = {The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors},
volume = {65},
year = {2016}
}
TY - JOUR
ID - 1369176
AU - Demlová, Regina - Valík, Dalibor - Obermannová, Radka - Zdražilová Dubská, Lenka
PY - 2016
TI - The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors
JF - Physiological Research
VL - 65
IS - Suppl. 4
SP - "S455"-"S462"
EP - "S455"-"S462"
PB - Fyziologický ústav AV ČR
SN - 08628408
KW - Cancer treatment
KW - Monoclonal antibodies
KW - Immune checkpoint inhibitors
KW - Immune related adverse events
N2 - Monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic strategies for both hematologic malignancies and solid tumors. In addition to targeting cancer antigens antibodies can also modulate immunological pathways that are critical to immune surveillance. Antibody therapy directed against several negative immunologic regulators (checkpoints) is demonstrating significant success in the past few years. Immune checkpoint inhibitors, ipilimumab, pembrolizumab and nivolumab, have shown significant clinical benefit in several malignancies and are already approved for advanced melanoma and squamous NSCLC. Based on their mechanism of action, these agents can exert toxicities that are unlike conventional cytotoxic chemotherapy, whose nature is close to autoimmune diseases - immune related adverse events (irAEs). In this review we focus on the spectrum of irAEs associated with immune checkpoint antibodies, discussing the pharmacological treatment strategy and possible clinical impact.
ER -
DEMLOVÁ, Regina, Dalibor VALÍK, Radka OBERMANNOVÁ a Lenka ZDRAŽILOVÁ DUBSKÁ. The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors. \textit{Physiological Research}. Praha: Fyziologický ústav AV ČR, 2016, roč.~65, Suppl. 4, s.~''S455''-''S462'', 8 s. ISSN~0862-8408.
|
